FSY

fevipiprant

Created:	2018-04-16
Last modified:	2021-03-13

Find Related PDB Entry
1 entries where FSY is found as a standalone ligand

Find related ligands:

Similar Ligands (Stereospecific) Similar Ligands (including Stereoisomers) Similar Ligands (Quick Screen) Similar Ligands (Substructure Stereospecific) Similar Ligands (Substructure including Stereoisomers)

Chemical Details
Formal Charge	0
Atom Count	46
Chiral Atom Count	0
Bond Count	48
Aromatic Bond Count	16

2D diagram of FSY

Toggle Hydrogen Toggle Labels

Chemical Component Summary
Name	fevipiprant
Synonyms	(2-methyl-1-{[4-(methylsulfonyl)-2-(trifluoromethyl)phenyl]methyl}-1H-pyrrolo[2,3-b]pyridin-3-yl)acetic acid
Systematic Name (OpenEye OEToolkits)	2-[2-methyl-1-[[4-methylsulfonyl-2-(trifluoromethyl)phenyl]methyl]pyrrolo[2,3-b]pyridin-3-yl]ethanoic acid
Formula	C₁₉ H₁₇ F₃ N₂ O₄ S
Molecular Weight	426.409
Type	NON-POLYMER

Chemical Descriptors
Type	Program	Version	Descriptor
SMILES	ACDLabs	12.01	OC(Cc1c3c(n(c1C)Cc2ccc(cc2C(F)(F)F)S(=O)(=O)C)nccc3)=O
SMILES	CACTVS	3.385	Cc1n(Cc2ccc(cc2C(F)(F)F)[S](C)(=O)=O)c3ncccc3c1CC(O)=O
SMILES	OpenEye OEToolkits	2.0.6	Cc1c(c2cccnc2n1Cc3ccc(cc3C(F)(F)F)S(=O)(=O)C)CC(=O)O
Canonical SMILES	CACTVS	3.385	Cc1n(Cc2ccc(cc2C(F)(F)F)[S](C)(=O)=O)c3ncccc3c1CC(O)=O
Canonical SMILES	OpenEye OEToolkits	2.0.6	Cc1c(c2cccnc2n1Cc3ccc(cc3C(F)(F)F)S(=O)(=O)C)CC(=O)O
InChI	InChI	1.03	InChI=1S/C19H17F3N2O4S/c1-11-15(9-17(25)26)14-4-3-7-23-18(14)24(11)10-12-5-6-13(29(2,27)28)8-16(12)19(20,21)22/h3-8H,9-10H2,1-2H3,(H,25,26)
InChIKey	InChI	1.03	GFPPXZDRVCSVNR-UHFFFAOYSA-N

Drug Info: DrugBank

DrugBank ID	DB12011
Name	Fevipiprant
Groups	investigational
Description	Fevipiprant has been used in trials studying the treatment of Asthma, Atopic Dermatitis, and Allergic Rhinitis.
Synonyms	Fevipiprant
Categories	Heterocyclic Compounds, Fused-Ring Indoles
CAS number	872365-14-5

Related Resource References

Resource Name	Reference
Pharos	CHEMBL3137332
PubChem	23582412
ChEMBL	CHEMBL3137332

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729.